ENLV
Enlivex Therapeutics Ltd
NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY
$0.82
-0.46% today
Updated 2026-05-01
Market cap
$197.61M
P/E ratio
0.03
P/S ratio
—
EPS (TTM)
$25.48
Dividend yield
—
52W range
$1 – $2
Volume
0.6M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C5.0
Quality
C+5.0
Profitability
C+6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$20.00
+2350.98%
12-Month target
$1.02
+25.00%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 126.20% — strong efficiency
Risks
- Thin margins at 0.00%
- Negative free cash flow $-2.91M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-31.06M | $-29.07M | $-15.01M | $1.24B | $1.24B |
| EPS | — | — | — | — | $25.48 |
| Free cash flow | $-32.08M | $-23.76M | $-13.11M | $-10.48M | $-2.91M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Enlivex Therapeutics Ltd trades at $0.82. representing a P/E of 0.03x trailing earnings. Our Smart Value Score of 36/100 indicates the stock is weak.
Frequently asked questions
What is Enlivex Therapeutics Ltd's stock price?
Enlivex Therapeutics Ltd (ENLV) trades at $0.82.
Is Enlivex Therapeutics Ltd overvalued?
Smart Value Score 36/100 (Grade D, Sell).
What is the price target of Enlivex Therapeutics Ltd (ENLV)?
The analyst target price is $20.00, representing +2351.0% upside from the current price of $0.82.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE126.20%
Beta1.68
50D MA$1.00
200D MA$1.06
Shares out0.24B
Float0.05B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—